MOLECULAR GENETICS

TMS (Tandem Mass Spectrometry) and other biochemical/enzymatic assays (Fluoroimmunoassay, etc.)
This comprehensive newborn screening panel integrates two primary methodologies to detect a broad spectrum of congenital, genetic, and metabolic disorders: * TMS (Tandem Mass Spectrometry): This is the core methodology for screening a large number of inborn errors of metabolism (IEMs). TMS analyzes abnormal levels of various metabolites (amino acids, acylcarnitines, succinylacetones, etc.) from a dried blood spot (DBS) sample. It is highly sensitive and specific for the rapid, simultaneous detection of 52 different metabolic conditions. * 52 Conditions by TMS: This extensively covers: * Amino Acid Disorders (Aminoacidopathies): Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Tyrosinemia (Types I, II, III), Citrullinemia, Argininemia, Argininosuccinic Acidemia, etc. * Organic Acid Disorders (Organic Acidemias): Propionic Acidemia, Methylmalonic Acidemia, Isovaleric Acidemia, Glutaric Acidemia Type I, 3-Methylcrotonyl-CoA Carboxylase Deficiency, Multiple Carboxylase Deficiency, etc. * Fatty Acid Oxidation Disorders: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD), Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCADD), Carnitine Uptake Defect, Carnitine Palmitoyl Transferase Deficiencies, etc. * Other Disorders: Including some lysosomal storage disorders and urea cycle disorders if their metabolites are detected by TMS. * Other Basic Biochemical/Enzymatic Assays (for the 7 Conditions): These are typically performed on dried blood spots and cover a foundational set of critical, treatable conditions that are not primarily detected by TMS, or are traditionally screened separately. These commonly include: * Congenital Hypothyroidism (CH): Detected by measuring Thyroid Stimulating Hormone (TSH) and/or Thyroxine (T4) using Fluoroimmunoassay (FIA) or similar methods. * Congenital Adrenal Hyperplasia (CAH): Detected by measuring 17-hydroxyprogesterone (17-OHP) using FIA or similar methods. * G6PD Deficiency (Glucose-6-Phosphate Dehydrogenase Deficiency): Detected by measuring G6PD enzyme activity. * Galactosemia: Detected by elevated total galactose or galactose-1-phosphate, or by measuring Galactose-1-Phosphate Uridyltransferase (GALT) enzyme activity. * Biotinidase Deficiency (BTD): Detected by measuring biotinidase enzyme activity. * Cystic Fibrosis (CF): Often screened by immunoreactive trypsinogen (IRT), with reflex DNA testing for common CFTR gene mutations if IRT is elevated. * Hemoglobinopathies (e.g., Sickle Cell Disease, Thalassemia): Often screened using HPLC (High-Performance Liquid Chromatography) or IEF (Isoelectric Focusing) to identify abnormal hemoglobin variants. (Note: While PKU is a "basic" condition often listed with the 7, it is effectively covered by TMS. Therefore, Hemoglobinopathies are commonly included as the 7th 'basic' condition in comprehensive panels like this, especially in countries with high prevalence like India.) This combined approach provides a robust and comprehensive screening for a vast number of treatable conditions, allowing for early detection and intervention before symptoms develop, which is crucial for preventing severe intellectual disability, developmental delays, organ damage, or even death.

Dried Blood Spot (DBS) / Whole Blood (WB) in EDTA Vacutainer
(The primary sample type for this panel is Dried Blood Spot (DBS), collected via a heel prick on a special filter paper card. Whole Blood (WB) in EDTA may be specifically required for certain "basic" tests like hemoglobinopathy screening (e.g., HPLC) or as a backup/confirmatory sample, depending on the specific lab's protocol.)

Accurate timing and proper sample collection are paramount for the reliability of this comprehensive newborn screening panel.
* Optimal Timing: The blood samples (Dried Blood Spot - DBS and/or Whole Blood - WB EDTA) should ideally be collected between 24 to 72 hours (1-3 days) of the baby's life. * Adequate Milk Feeding: It is crucial that the baby has received at least 24 hours of adequate milk feeding (breast milk or formula) prior to blood sample collection. Feeding activates metabolic pathways, allowing for the accumulation of metabolites necessary for accurate detection by TMS and other assays, thereby reducing the chance of false-negative results. * Heel Prick Collection (DBS): A few drops of blood are collected via a gentle heel prick onto a special filter paper card (Guthrie card). It is essential that the designated circles on the card are completely saturated with blood and that the blood soaks through to the back of the card. * Venipuncture (WB EDTA): If Whole Blood in EDTA is also required (e.g., for Hemoglobinopathies), standard venipuncture techniques should be used to collect the necessary volume. * No Fasting Required: Newborns should not be fasted for this test. Adequate feeding is essential. * Parental Consent: Informed consent from parents is typically obtained before performing the screening. * Accurate Information: Accurate demographic information for the baby, feeding status (breastfed/formula), gestational age, birth weight, and any medications taken by the mother during pregnancy or by the baby should be precisely recorded on the sample submission form. This information is vital for accurate interpretation of results.